HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.

AbstractBACKGROUND:
In chronic kidney disease (CKD) patients, the ability to excrete a phosphate load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) promote phosphaturia. Serum FGF23 concentration is considered an early biomarker of excess phosphate load and high levels of FGF23 have been associated with increased mortality. In the present study, we have evaluated the changes in plasma FGF23 after treatment with the phosphate binder lanthanum carbonate in patients with CKD-3 and a normal serum phosphate concentration.
METHODS:
Eighteen Caucasian CKD Stage 3a/3b patients with serum phosphate <4.5 mg/dL were recruited in a prospective longitudinal open-label study. Patients received a 4-week period of standardized phosphorus-restricted diet containing 0.8 g/Kg/day protein. Thereafter, the same diet was maintained and patients received lanthanum carbonate (750 mg with the three main meals) for 4 weeks.
RESULTS:
No significant changes were observed in serum phosphate, however, lanthanum carbonate significantly decreased urinary excretion of phosphate and fractional excretion of phosphate (P < 0.004). This was accompanied by a significant decrease in carboxyterminal FGF23 (median percent change from baseline -21.8% (interquartile range -4.5, -30%), P = 0.025). No changes were observed in PTH.
CONCLUSIONS:
In conclusion, lanthanum carbonate reduced phosphate load, as assessed by urinary phosphate excretion, and also reduced plasma FGF23 in CKD-3 patients. This occurs in the presence of unchanged normal serum phosphate levels.
AuthorsEmilio Gonzalez-Parra, Maria Luisa Gonzalez-Casaus, Antonio Galán, Alberto Martinez-Calero, Victor Navas, Mariano Rodriguez, Alberto Ortiz
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 26 Issue 8 Pg. 2567-71 (Aug 2011) ISSN: 1460-2385 [Electronic] England
PMID21436379 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • FGF23 protein, human
  • Phosphorus
  • lanthanum carbonate
  • Fibroblast Growth Factors
  • Lanthanum
  • Fibroblast Growth Factor-23
Topics
  • Aged
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors (blood)
  • Glomerular Filtration Rate
  • Humans
  • Kidney Failure, Chronic (blood, drug therapy, pathology)
  • Lanthanum (pharmacology)
  • Longitudinal Studies
  • Male
  • Phosphorus (metabolism)
  • Prognosis
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: